FLGT logo

Fulgent Genetics Inc. (FLGT)

$24.21

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on FLGT

Market cap

$676403190

EPS

-3.1

P/E ratio

--

Price to sales

1.85

Dividend yield

--

Beta

0.99982

Price on FLGT

Previous close

$24.08

Today's open

$24.12

Day's range

$23.39 - $24.23

52 week range

$13.46 - $31.04

Profile about FLGT

CEO

Ming Hsieh

Employees

1315

Headquarters

El Monte, CA

Exchange

NASDAQ Global Market

Shares outstanding

27939000

Issue type

Common Stock

FLGT industries and sectors

Healthcare

Medical Diagnostics & Screening

News on FLGT

Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Fulgent Genetics (FLGT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

news source

Zacks Investment Research • 11 hours ago

news preview

Fulgent Genetics, Inc. (FLGT) Q3 2026 Earnings Call Transcript

Fulgent Genetics, Inc. ( FLGT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Lauren Sloane - The Blueshirt Group, LLC Karan Patel - Piper Sandler & Co., Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Fulgent Genetics Q3 2026 Conference Call and Webcast Call. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.

news source

Seeking Alpha • Nov 6, 2026

news preview

What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call

Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift results. The company reaffirmed its full-year revenue forecast and narrowed its projected loss.

news source

MarketBeat • Nov 6, 2026

news preview

Fulgent Reports Third Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026. Third Quarter 2026 Results: Revenue of $90.4 million GAAP loss of $13.2 million, or $(0.48) per share Non-GAAP loss of $2.4 million, or $(0.09) per share Adjusted EBITDA loss of $7.5 million No.

news source

Business Wire • Nov 5, 2026

news preview

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.14 per share a year ago.

news source

Zacks Investment Research • Nov 6, 2026

news preview

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer q.

news source

Business Wire • Oct 15, 2026

news preview

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.

news source

Zacks Investment Research • Sep 22, 2026

news preview

Think Outside the Box With These 3 Companies That Make Unusual Business Models Work

Some of the most successful companies started with business models that likely seemed unusual at first. Investors willing to take a chance on what may appear to be a quirky approach could find a surprisingly strong set of financials and a compelling case for future growth.

news source

MarketBeat • Sep 21, 2026

news preview

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Jul 31, 2026

news preview

Fulgent Genetics Q2 Earnings Call Highlights

Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.

news source

MarketBeat • Jul 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Fulgent Genetics Inc.

Open an M1 investment account to buy and sell Fulgent Genetics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in FLGT on M1